{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:00:37Z","timestamp":1790816437203,"version":"4.1.0"},"reference-count":238,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015918","name":"Dipartimento di Scienze Mediche, Universit\u00e0 degli Studi di Torino","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015918","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Breast cancer is one of the most common malignancies in women, with high morbidity and mortality rates. In breast cancer, the use of novel radiopharmaceuticals in nuclear medicine can improve the accuracy of diagnosis and staging, refine surveillance strategies and accuracy in choosing personalized treatment approaches, including radioligand therapy. Nuclear medicine thus shows great promise for improving the quality of life of breast cancer patients by allowing non-invasive assessment of the diverse and complex biological processes underlying the development of breast cancer and its evolution under therapy. This review aims to describe molecular probes currently in clinical use as well as those under investigation holding great promise for personalized medicine and precision oncology in breast cancer.<\/jats:p>","DOI":"10.3389\/fmed.2022.881551","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T05:27:10Z","timestamp":1649741230000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review"],"prefix":"10.3389","volume":"9","author":[{"given":"Michele","family":"Balma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Liberini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Racca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Laudicella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bauckneht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Buschiazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele Giovanni","family":"Nicolotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Peano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natale","family":"Quartuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Abgral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Daniela","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"D'Alessandria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Terreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin William","family":"Huellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Papaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"Deandreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Prim."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00259-019-04553-8","article-title":"Good clinical practice recommendations for the use of PET\/CT in oncology","volume":"47","author":"Sala\u00fcn","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1053\/j.semnuclmed.2021.04.005","article-title":"PET\/CT variants and pitfalls in breast cancers","volume":"51","author":"Kikano","year":"2021","journal-title":"Semin Nucl Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000509025","article-title":"Histology of luminal breast cancer","volume":"15","author":"Erber","year":"2020","journal-title":"Breast Care."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"102286","DOI":"10.1016\/j.ctrv.2021.102286","article-title":"Targeting HER2 heterogeneity in breast cancer","volume":"100","author":"Hamilton","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature."},{"key":"B11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3390\/jpm11080808","article-title":"Breast cancer treatments: updates and new challenges","volume":"11","author":"Burguin","year":"2021","journal-title":"J Pers Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5694","DOI":"10.3390\/cancers13225694","article-title":"Triple-negative breast cancer histological subtypes with a favourable prognosis","volume":"13","author":"Cserni","year":"2021","journal-title":"Cancers."},{"key":"B14","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3390\/biology10090834","article-title":"Intrinsic subtypes and androgen receptor gene expression in primary breast cancer. A meta-analysis","volume":"10","author":"Cruz-Tapias","year":"2021","journal-title":"Biology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1155\/2012\/710561","article-title":"PET tracers for clinical imaging of breast cancer","volume":"2012","author":"Pe\u00f1uelas","year":"2012","journal-title":"J Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/RLU.0000000000003502","article-title":"Impact of 18F-FDG PET, PET\/CT, and PET\/MRI on staging and management as an initial staging modality in breast cancer: a systematic review and meta-analysis","volume":"46","author":"Han","year":"2021","journal-title":"Clin Nucl Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2214\/AJR.19.21177","article-title":"PET\/CT for patients with breast cancer: where is the clinical impact?","volume":"213","author":"Ulaner","year":"2019","journal-title":"Am J Roentgenol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00259-002-0880-8","article-title":"FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters","volume":"29","author":"Buck","year":"2002","journal-title":"Eur J Nucl Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s00330-013-3037-1","article-title":"18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes","volume":"24","author":"Koo","year":"2014","journal-title":"Eur Radiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00259-015-3070-1","article-title":"Association between 18F-FDG uptake and molecular subtype of breast cancer","volume":"42","author":"Kitajima","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S11912-020-00940-9","article-title":"Application of PET tracers in molecular imaging for breast cancer","volume":"22","author":"Boers","year":"2020","journal-title":"Curr Oncol Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11604-015-0516-0","article-title":"Present and future role of FDG-PET\/CT imaging in the management of breast cancer","volume":"34","author":"Kitajima","year":"2016","journal-title":"Jpn J Radiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11604-013-0270-0","article-title":"Prevalence and clinical significance of incidental F18-FDG breast uptake: a systematic review and meta-analysis","volume":"32","author":"Bertagna","year":"2014","journal-title":"Jpn J Radiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/annonc\/mdq345","article-title":"International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment","volume":"22","author":"Dawood","year":"2011","journal-title":"Ann Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/j.semnuclmed.2007.01.001","article-title":"Increased 18F-Fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography\/computed tomography (PET\/CT): accumulated data from four years of experience with PET\/CT","volume":"37","author":"Metser","year":"2007","journal-title":"Semin Nucl Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e190037","DOI":"10.1148\/rycan.2020190037","article-title":"Management of incidental breast lesions detected at nuclear medicine examinations","volume":"2","author":"Tania Rahman","year":"2020","journal-title":"Radiol Imaging Cancer."},{"key":"B28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/RLU.0000000000001203","article-title":"Spectrum of the breast lesions with increased 18F-FDG uptake on PET\/CT","volume":"41","author":"Dong","year":"2016","journal-title":"Clin Nucl Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1007\/s12149-020-01525-z","article-title":"Metabolic changes in breast cancer on dual-time-point 18F-FDG PET\/CT imaging according to primary tumor uptake and background parenchymal enhancement","volume":"34","author":"Kim","year":"2020","journal-title":"Ann Nucl Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-6315-8","article-title":"Dual time point 18F-fluorodeoxyglucose positron emission tomography\/computed tomography fusion imaging (18F-FDG PET\/CT) in primary breast cancer","volume":"19","author":"Yamagishi","year":"2019","journal-title":"BMC Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/metabo7020018","article-title":"Metabolic portraits of breast cancer by HR MAS MR spectroscopy of intact tissue samples","volume":"7","author":"Haukaas","year":"2017","journal-title":"Metabolites."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/bjc.1991.475","article-title":"Uptake of 11C-methionine in breast cancer studied by PET.An association with the size of S-phase fraction","volume":"64","author":"Leskinen-Kallio","year":"1991","journal-title":"Br J Cancer."},{"key":"B33","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/bjc.1993.143","article-title":"Carbon-11-methionine and pet in evaluation of treatment response of breast cancer","volume":"67","author":"Huovinen","year":"1993","journal-title":"Br J Cancer."},{"key":"B34","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cpet.2018.02.009","article-title":"Amino acid metabolism as a target for breast cancer imaging","volume":"13","author":"Ulaner","year":"2018","journal-title":"PET Clin."},{"key":"B35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/MNM.0b013e328313b7bc","article-title":"Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer","volume":"30","author":"Lindholm","year":"2009","journal-title":"Nucl Med Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.1995.13.6.1470","article-title":"Positron emission tomography studies in patients with locally advanced and\/or metastatic breast cancer: a method for early therapy evaluation?","volume":"13","author":"Jansson","year":"1995","journal-title":"J Clin Oncol."},{"key":"B37","first-page":"1472","article-title":"Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors","volume":"37","author":"Inoue","year":"1996","journal-title":"J Nucl Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2967\/JNUMED.113.121418","article-title":"(18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment","volume":"55","author":"Lizarraga","year":"2014","journal-title":"J Nucl Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/CANCERS14040879","article-title":"What does pet imaging bring to neuro-oncology in 2022? A review","volume":"14","author":"Zhang-Yin","year":"2022","journal-title":"Cancers."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41181-019-0058-3","article-title":"Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers","volume":"4","author":"Bauckneht","year":"2019","journal-title":"EJNMMI radiopharm chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.2967\/jnumed.112.118125","article-title":"Evaluation of the biodistribution of 11C-methionine in children and young adults","volume":"54","author":"Harris","year":"2013","journal-title":"J Nucl Med."},{"key":"B42","first-page":"406","article-title":"Clinical utility of (18)F-Fluciclovine PET\/CT in recurrent prostate cancer with very low (\u2264 0.3 ng\/mL) prostate-specific antigen levels","volume":"11","author":"Marcus","year":"2021","journal-title":"Am J Nucl Med Mol Imaging."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3390\/cancers11091348","article-title":"18F-FACBC in prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Laudicella","year":"2019","journal-title":"Cancers."},{"key":"B44","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3390\/diagnostics11020304","article-title":"18f-fluciclovine positron emission tomography in prostate cancer: a systematic review and diagnostic meta-analysis","volume":"11","author":"Biscontini","year":"2021","journal-title":"Diagnostics."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.2967\/jnumed.115.170456","article-title":"Initial results of a prospective clinical trial of 18FFluciclovine PET\/CT in newly diagnosed invasive ductal and invasive lobular breast cancers","volume":"57","author":"Ulaner","year":"2016","journal-title":"J Nucl Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2967\/jnumed.115.171389","article-title":"Anti-3-18F-FACBC (18F-Fluciclovine) PET\/CT of breast cancer: an exploratory study","volume":"57","author":"Tade","year":"2016","journal-title":"J Nucl Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2967\/jnumed.116.183335","article-title":"Prospective clinical trial of 18F-fluciclovine PET\/CT for determining the response to neoadjuvant therapy in invasive ductal and invasive lobular breast cancers","volume":"58","author":"Ulaner","year":"2017","journal-title":"J Nucl Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1158\/1078-0432.CCR-12-0214","article-title":"Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L- glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer","volume":"18","author":"Baek","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2967\/jnumed.116.180661","article-title":"18F-5-Fluoroaminosuberic acid as a potential tracer to gauge oxidative stress in breast cancer models","volume":"58","author":"Yang","year":"2017","journal-title":"J Nucl Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2967\/jnumed.113.126664","article-title":"Functional imaging of oxidative stress with a novel PET imaging agent, 18f-5-fluoro-l-aminosuberic acid","volume":"55","author":"Webster","year":"2014","journal-title":"J Nucl Med."},{"key":"B51","first-page":"692","article-title":"Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]Tyrosine PET","volume":"38","author":"Kole","year":"1997","journal-title":"J Nucl Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1158\/0008-5472.CAN-16-1945","article-title":"[18F](2S,4R)4-fluoroglutamine PET detects glutamine pool size changes in triple-negative breast cancer in response to glutaminase inhibition","volume":"77","author":"Zhou","year":"2017","journal-title":"Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"B54","doi-asserted-by":"publisher","first-page":"89S","DOI":"10.2967\/jnumed.115.157958","article-title":"The use of novel PET tracers to image breast cancer biologic processes such as proliferation, DNA damage and repair, and angiogenesis","volume":"57","author":"Kenny","year":"2016","journal-title":"J Nucl Med."},{"key":"B55","first-page":"614","article-title":"Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies","volume":"40","author":"Mankoff","year":"1999","journal-title":"J Nucl Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cpet.2009.04.012","article-title":"PET radiotracers for imaging the proliferative status of solid tumors","volume":"4","author":"Mach","year":"2009","journal-title":"PET Clin."},{"key":"B57","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.rcl.2004.09.005","article-title":"PET imaging of cellular proliferation","volume":"43","author":"Mankoff","year":"2005","journal-title":"Radiol Clin North Am."},{"key":"B58","first-page":"1757","article-title":"Carbon-11-thymidine and FDG to measure therapy response","volume":"39","author":"Shields","year":"1998","journal-title":"J Nucl Med."},{"key":"B59","first-page":"290","article-title":"Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging","volume":"37","author":"Shields","year":"1996","journal-title":"J Nucl Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1007\/s00259-004-1462-8","article-title":"PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study","volume":"31","author":"Smyczek-Gargya","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1016\/j.ejca.2012.05.001","article-title":"Correlation between Ki-67 immunohistochemistry and 18F-Fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis","volume":"48","author":"Chalkidou","year":"2012","journal-title":"Eur J Cancer."},{"key":"B62","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.2967\/jnumed.107.046391","article-title":"Imaging of cell proliferation: status and prospects","volume":"49","author":"Bading","year":"2008","journal-title":"J Nucl Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.3390\/cancers13215459","article-title":"Radionuclide-based imaging of breast cancer: state of the art","volume":"13","author":"Li","year":"2021","journal-title":"Cancers."},{"key":"B64","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.semnuclmed.2013.02.003","article-title":"Novel methods and tracers for breast cancer imaging","volume":"43","author":"Linden","year":"2013","journal-title":"Semin Nucl Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11307-005-0029-9","article-title":"Usefulness of 3\u2032-[F-18]fluoro-3\u2032-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy","volume":"8","author":"Pio","year":"2006","journal-title":"Mol Imaging Biol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00259-007-0379-4","article-title":"Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3\u2032-deoxy-3\u2032-[18F]fluorothymidine positron emission tomography","volume":"34","author":"Kenny","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.3390\/cancers13143511","article-title":"Early imaging and molecular changes with neoadjuvant bevacizumab in stage ii\/iii breast cancer","volume":"13","author":"L\u00f3pez-Vega","year":"2021","journal-title":"Cancers."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13058-021-01464-1","article-title":"18 F-fluorodeoxyglucose (FDG) PET or 18 F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study","volume":"23","author":"Romine","year":"2021","journal-title":"Breast Cancer Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12885-021-08649-Z","article-title":"Prospective comparison of early interim 18 F-FDG-PET with 18 F-FLT-PET for predicting treatment response and survival in metastatic breast cancer","volume":"21","author":"Su","year":"2021","journal-title":"BMC Cancer."},{"key":"B70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00259-004-1713-8","article-title":"Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer","volume":"32","author":"Sun","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s00259-008-0738-9","article-title":"Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2","volume":"35","author":"Tehrani","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B72","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/sj.bjc.6690789","article-title":"Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells","volume":"81","author":"Al-Nabulsi","year":"1999","journal-title":"Br J Cancer."},{"key":"B73","doi-asserted-by":"publisher","first-page":"350","DOI":"10.2967\/jnumed.112.111948","article-title":"Assessment of cellular proliferation in tumors by PET using 18F-ISO-1","volume":"54","author":"Dehdashti","year":"2013","journal-title":"J Nucl Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2967\/jnumed.119.232363","article-title":"Breast cancer 18F-ISO-1 uptake as a marker of proliferation status","volume":"61","author":"McDonald","year":"2020","journal-title":"J Nucl Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/CMAR.S58285","article-title":"Progress toward overcoming hypoxia-induced resistance to solid tumor therapy","volume":"7","author":"Karakashev","year":"2015","journal-title":"Cancer Manag Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0305-7372(03)00003-3","article-title":"Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies","volume":"29","author":"Shannon","year":"2003","journal-title":"Cancer Treat Rev."},{"key":"B77","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/bjc.2014.610","article-title":"Imaging tumour hypoxia with positron emission tomography","volume":"112","author":"Fleming","year":"2015","journal-title":"Br J Cancer."},{"key":"B78","first-page":"2133","article-title":"Hypoxia in human gliomas: demonstration by PET with fluorine-18- fluoromisonidazole","volume":"33","author":"Valk","year":"1992","journal-title":"J Nucl Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00259-010-1453-x","article-title":"Radionuclide imaging of perfusion and hypoxia","volume":"37","author":"Laking","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1158\/1078-0432.CCR-0688-3","article-title":"Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]Fluoromisonidazole and [18F]Fluorodeoxyglucose positron emission tomography imaging","volume":"10","author":"Rajendran","year":"2004","journal-title":"Clin Cancer Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2967\/jnumed.112.111963","article-title":"18F-fluoromisonidazole PET\/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer","volume":"54","author":"Cheng","year":"2013","journal-title":"J Nucl Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/RLU.0000000000000286","article-title":"Head and neck tumor hypoxia imaging by 18F-fluoroazomycin- arabinoside (18F-FAZA)-PET: a review","volume":"39","author":"Halmos","year":"2014","journal-title":"Clin Nucl Med."},{"key":"B83","first-page":"365","article-title":"PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence","volume":"4","author":"Lopci","year":"2014","journal-title":"Am J Nucl Med Mol Imaging."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.2967\/jnumed.109.069021","article-title":"Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer","volume":"50","author":"Lohith","year":"2009","journal-title":"J Nucl Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.107.048520","article-title":"Assessing tumor hypoxia in cervical cancer by PET with 60Cu- labeled diacetyl-bis(N4-methylthiosemicarbazone)","volume":"49","author":"Dehdashti","year":"2008","journal-title":"J Nucl Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s10350-008-9420-3","article-title":"Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study","volume":"51","author":"Dietz","year":"2008","journal-title":"Dis Colon Rectum."},{"key":"B87","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3174\/ajnr.A3159","article-title":"Application of 62Cu-diacetyl-bis (N4- methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1\u03b1 expression in patients with glioma","volume":"34","author":"Tateishi","year":"2013","journal-title":"Am J Neuroradiol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/RLU.0b013e318279fd3d","article-title":"Hypoxia imaging with 18F-fluoroerythronitroimidazole integrated PET\/CT and immunohistochemical studies in non-small cell lung cancer","volume":"38","author":"Hu","year":"2013","journal-title":"Clin Nucl Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11307-013-0670-7","article-title":"Standardized uptake value in high uptake area on positron emission tomography with 18F-FRP170 as a hypoxic cell tracer correlates with intratumoral oxygen pressure in glioblastoma","volume":"16","author":"Beppu","year":"2014","journal-title":"Mol Imaging Biol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.radonc.2013.08.031","article-title":"Hypoxia imaging with [18F]HX4 PET in NSCLC patients: defining optimal imaging parameters","volume":"109","author":"Zegers","year":"2013","journal-title":"Radiother Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ejca.2013.10.004","article-title":"A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases","volume":"50","author":"Aurilio","year":"2014","journal-title":"Eur J Cancer."},{"key":"B92","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0022-5347(05)64132-8","article-title":"Expression of estrogen receptors \u03b1 and \u03b2 by sympathetic ganglion neurons projecting to the proximal urethra of female rats","volume":"169","author":"Zoubina","year":"2003","journal-title":"J Urol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev.physiol.63.1.165","article-title":"Role of estrogen receptor beta in estrogen action","volume":"63","author":"Pettersson","year":"2001","journal-title":"Annu Rev Physiol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0039-128X(02)00025-9","article-title":"18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals","volume":"67","author":"Seimbille","year":"2002","journal-title":"Steroids."},{"key":"B95","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF02988592","article-title":"Biodistribution and breast tumor uptake of 16\u03b1-[18F]-fluoro-17 \u03b2- estradiol in rat","volume":"14","author":"Sasaki","year":"2000","journal-title":"Ann Nucl Med."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262500","article-title":"Biodistribution of 18F-FES in patients with metastatic ER+ breast cancer undergoing treatment with Rintodestrant (G1T48), a novel selective estrogen receptor degrader","author":"Iqbal","year":"2021","journal-title":"J Nucl Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0969-8051(97)00002-4","article-title":"Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16\u03b1-Fluorestradiol (FES)","volume":"24","author":"Mankoff","year":"1997","journal-title":"Nucl Med Biol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1148\/radiology.169.1.3262228","article-title":"Breast cancer: PET imaging of estrogen receptors","volume":"169","author":"Mintun","year":"1988","journal-title":"Radiology."},{"key":"B99","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1634\/theoncologist.2019-0967","article-title":"Whole-body characterization of estrogen receptor status in metastatic breast cancer with 16\u03b1-18F-Fluoro-17\u03b2-estradiol positron emission tomography: meta-analysis and recommendations for integration into clinical applications","volume":"25","author":"Kurland","year":"2020","journal-title":"Oncologist."},{"key":"B100","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/diagnostics10100756","article-title":"Image quality and interpretation of [18F]-FES-PET: is there any effect of food intake?","volume":"10","author":"Boers","year":"2020","journal-title":"Diagnostics."},{"key":"B101","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/RLU.0000000000001347","article-title":"Recommendations and technical aspects of 16\u03b1-[18F]Fluoro-17\u03b2-Estradiol PET to image the estrogen receptor in vivo","volume":"41","author":"Venema","year":"2016","journal-title":"Clin Nucl Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e1277","DOI":"10.1634\/theoncologist.2019-0096","article-title":"18 F-FES PET\/CT influences the staging management of patients with newly diagnosed estrogen receptor-positive breast cancer: a retrospective comparative study with 18 F-FDG PET\/CT","volume":"24","author":"Liu","year":"2019","journal-title":"Oncologist."},{"key":"B103","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2967\/jnumed.120.247882","article-title":"Head-to-head evaluation of 18F-FES and 18F-FDG PET\/CT in metastatic invasive lobular breast cancer","volume":"62","author":"Ulaner","year":"2021","journal-title":"J Nucl Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.2967\/jnumed.120.256826","article-title":"Value of 18 F-FES PET in solving clinical dilemmas in breast cancer patients: a retrospective study","volume":"62","author":"Boers","year":"2021","journal-title":"J Nucl Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11307-013-0699-7","article-title":"A phase 2 study of 16\u03b1-[18F]-fluoro-17\u03b2-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)","volume":"16","author":"Peterson","year":"2014","journal-title":"Mol Imaging Biol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1158\/1078-0432.CCR-10-3321","article-title":"Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer","volume":"17","author":"Linden","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1007\/s00259-015-3107-5","article-title":"Positron emission tomography of tumour [18F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy","volume":"42","author":"van Kruchten","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-06903-8","article-title":"A preliminary study of 18F-FES PET\/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel","volume":"7","author":"Gong","year":"2017","journal-title":"Sci Rep."},{"key":"B109","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10549-008-9953-0","article-title":"PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer","volume":"113","author":"Dehdashti","year":"2009","journal-title":"Breast Cancer Res Treat."},{"key":"B110","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2174\/1874471009666161019144950","article-title":"18F-fluoroestradiol positron emission tomography in breast cancer patients: systematic review of the literature & meta-analysis","volume":"9","author":"Evangelista","year":"2016","journal-title":"Curr Radiopharm."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e78192","DOI":"10.1371\/journal.pone.0078192","article-title":"Can positron emission tomography\/computed tomography with the dual tracers fluorine-18 fluoroestradiol and fluorodeoxyglucose predict neoadjuvant chemotherapy response of breast cancer? -A pilot study","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS ONE."},{"key":"B112","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2967\/jnumed.117.194654","article-title":"Improved estrogen receptor assessment by PET using the novel radiotracer 18 F-4FMFES in estrogen receptor\u2013positive breast cancer patients: an ongoing phase II clinical trial","volume":"59","author":"Paquette","year":"2018","journal-title":"J Nucl Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.nucmedbio.2018.01.003","article-title":"18 F\u2013labeled estradiol derivative for targeting estrogen receptor-expressing breast cancer","volume":"59","author":"Xu","year":"2018","journal-title":"Nucl Med Biol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"907","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical oncology\/college of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch Pathol Lab Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0092-8674(02)00641-4","article-title":"Combinatorial control of gene expression by nuclear receptors and coregulators","volume":"108","author":"McKenna","year":"2002","journal-title":"Cell."},{"key":"B116","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jsbmb.2013.04.003","article-title":"Progesterone receptor targeting with radiolabelled steroids: an approach in predicting breast cancer response to therapy","volume":"137","author":"Cunha","year":"2013","journal-title":"J Steroid Biochem Mol Biol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10549-009-0501-3","article-title":"An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers","volume":"121","author":"Natrajan","year":"2010","journal-title":"Breast Cancer Res Treat."},{"key":"B118","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1200\/JCO.2007.11.9453","article-title":"Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98","volume":"25","author":"Viale","year":"2007","journal-title":"J Clin Oncol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.tem.2004.07.004","article-title":"Steroid receptors in human breast cancer","volume":"15","author":"Clarke","year":"2004","journal-title":"Trends Endocrinol Metab."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1021\/jm00402a019","article-title":"21-[18F]Fluoro-16\u03b1-ethyl-19-norprogesterone: synthesis and target tissue selective uptake of a progestin receptor based radiotracer for positron emission tomography","volume":"31","author":"Pomper","year":"1988","journal-title":"J Med Chem."},{"key":"B121","first-page":"1532","article-title":"Assessment of 21-[18F]fluoro-16\u03b1-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas","volume":"32","author":"Dehdashti","year":"1991","journal-title":"J Nucl Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/0969-8051(94)90083-3","article-title":"Metabolism of a [18F]fluorine labeled progestin (21 -[18F]fluoro-16\u03b1 -ethyl-19-norprogesterone) in humans: a clue for future investigations","volume":"21","author":"Verhagen","year":"1994","journal-title":"Nucl Med Biol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/0969-8051(94)00142-7","article-title":"6\u03b1-[18F]Fluoroprogesterone: synthesis via halofluorination-oxidation, receptor binding and tissue distribution","volume":"22","author":"Choe","year":"1995","journal-title":"Nucl Med Biol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1021\/jm00002a014","article-title":"Fluorine-18-labeled progestin 16\u03b1, 17\u03b1-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity","volume":"38","author":"Buckman","year":"1995","journal-title":"J Med Chem."},{"key":"B125","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1021\/jo020190r","article-title":"An efficient route for the preparation of a 21-fluoro progestin-16\u03b1,17\u03b1-dioxolane, a high-affinity ligand for PET imaging of the progesterone receptor","volume":"67","author":"Vijaykumar","year":"2002","journal-title":"J Org Chem."},{"key":"B126","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2967\/jnumed.111.098319","article-title":"Assessment of progesterone receptors in breast carcinoma by PET with 21- 18F-fluoro-16\u03b1,17\u03b1-[(R)-(1\u2032-\u03b1- furylmethylidene) dioxy]-19-norpregn-4-ene-3,20-dione","volume":"53","author":"Dehdashti","year":"2012","journal-title":"J Nucl Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2967\/jnumed.112.103465","article-title":"Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer","volume":"53","author":"Fowler","year":"2012","journal-title":"J Nucl Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-20814-9","article-title":"Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy","volume":"12","author":"Dehdashti","year":"2021","journal-title":"Nat Commun."},{"key":"B129","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1038\/sj.onc.1203973","article-title":"Molecular mechanisms underlying ErbB2\/HER2 action in breast cancer","volume":"19","author":"Harari","year":"2000","journal-title":"Oncogene."},{"key":"B130","first-page":"1045","article-title":"The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies","volume":"10","author":"Kreutzfeldt","year":"2020","journal-title":"Am J Cancer Res."},{"key":"B131","first-page":"12","article-title":"Diagnostic HER2-binding radiopharmaceutical, [68Ga]Ga-ABY-025, for routine clinical use in breast cancer patients","volume":"9","author":"Velikyan","year":"2019","journal-title":"Am J Nucl Med Mol Imaging."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3390\/diagnostics11091555","article-title":"Breast cancer heterogeneity","volume":"11","author":"Fumagalli","year":"2021","journal-title":"Diagnostics."},{"key":"B133","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2174\/138920111795164039","article-title":"Imaging cellular receptors in breast cancers: an overview","volume":"12","author":"Sekar","year":"2011","journal-title":"Curr Pharm Biotechnol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"B135","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/ph5010079","article-title":"89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors","volume":"5","author":"Chang","year":"2012","journal-title":"Pharmaceuticals."},{"key":"B136","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/clpt.2010.12","article-title":"Biodistribution of 89 Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer","volume":"87","author":"Dijkers","year":"2010","journal-title":"Clin Pharmacol Ther."},{"key":"B137","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s11307-016-0951-z","article-title":"[89Zr]Trastuzumab: evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer","volume":"18","author":"Laforest","year":"2016","journal-title":"Mol Imaging Biol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/annonc\/mdv577","article-title":"Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial","volume":"27","author":"Gebhart","year":"2016","journal-title":"Ann Oncol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1007\/s00259-018-4099-8","article-title":"89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up","volume":"45","author":"Bensch","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2967\/jnumed.112.118612","article-title":"64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer","volume":"54","author":"Tamura","year":"2013","journal-title":"J Nucl Med."},{"key":"B141","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2967\/jnumed.113.122630","article-title":"Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using 64Cu-DOTA-trastuzumab PET","volume":"55","author":"Mortimer","year":"2014","journal-title":"J Nucl Med."},{"key":"B142","doi-asserted-by":"publisher","first-page":"191","DOI":"10.23736\/S1824-4785.16.02867-3","article-title":"Copper-64 trastuzumab PET imaging: a reproducibility study","volume":"63","author":"Carrasquillo","year":"2019","journal-title":"Q J Nucl Med Mol Imaging."},{"key":"B143","doi-asserted-by":"publisher","first-page":"892","DOI":"10.2967\/jnumed.109.073239","article-title":"Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled Affibody molecules","volume":"51","author":"Baum","year":"2010","journal-title":"J Nucl Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7150\/thno.13502","article-title":"Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET\/CT","volume":"6","author":"S\u00f6rensen","year":"2016","journal-title":"Theranostics."},{"key":"B145","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2967\/jnumed.115.169342","article-title":"Biodistribution and radiation dosimetry of the anti-HER2 Affibody molecule 68Ga-ABY-025 in breast cancer patients","volume":"57","author":"Sandstr\u00f6m","year":"2016","journal-title":"J Nucl Med."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00259-017-3650-3","article-title":"Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT","volume":"44","author":"Sandberg","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3389\/fphar.2020.579068","article-title":"The biological functions and clinical applications of integrins in cancers","volume":"11","author":"Su","year":"2020","journal-title":"Front Pharmacol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.7150\/jca.44313","article-title":"Angiogenesis in breast cancer progression, diagnosis, and treatment","volume":"11","author":"Madu","year":"2020","journal-title":"J Cancer."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41388-020-01588-2","article-title":"Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance","volume":"40","author":"Yousefi","year":"2021","journal-title":"Oncogene."},{"key":"B150","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1758834010397627","article-title":"Bevacizumab in metastatic breast cancer: when may it be used?","volume":"3","author":"Goldfarb","year":"2011","journal-title":"Ther Adv Med Oncol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1007\/s00259-021-05352-w","article-title":"Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas","volume":"48","author":"Laudicella","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B152","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7150\/thno\/v01p0048","article-title":"PET imaging of integrin \u03b1V\u03b23 expression","volume":"1","author":"Beer","year":"2012","journal-title":"Theranostics."},{"key":"B153","doi-asserted-by":"publisher","first-page":"e168248","DOI":"10.1371\/journal.pone.0168248","article-title":"68Ga-TRAP-(RGD)3 hybrid imaging for the in vivo monitoring of \u03b1v\u03b23-integrin expression as biomarker of anti-angiogenic therapy effects in experimental breast cancer","volume":"11","author":"Kazmierczak","year":"2016","journal-title":"PLoS ONE."},{"key":"B154","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2967\/jnumed.107.045526","article-title":"Patterns of \u03b1v\u03b23 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET","volume":"49","author":"Beer","year":"2008","journal-title":"J Nucl Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/cbr.2014.1747","article-title":"First-in-human study demonstrating tumor-angiogenesis by PET\/CT imaging with 68Ga-NODAGA-THERANOST, a high-affinity peptidomimetic for \u03b1v\u03b23 integrin receptor targeting","volume":"30","author":"Baum","year":"2015","journal-title":"Cancer Biother Radiopharm."},{"key":"B156","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MNM.0b013e32834471ff","article-title":"Novel PET biomarkers for breast cancer imaging","volume":"32","author":"Kenny","year":"2011","journal-title":"Nucl Med Commun."},{"key":"B157","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2967\/jnumed.107.049452","article-title":"Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients","volume":"49","author":"Kenny","year":"2008","journal-title":"J Nucl Med."},{"key":"B158","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1007\/s00259-011-1907-9","article-title":"Quantification of receptor-ligand binding with [18F]fluciclatide in metastatic breast cancer patients","volume":"38","author":"Tomasi","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B159","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1148\/radiol.14140028","article-title":"18F-FPPRGD2 PET\/CT: pilot phase evaluation of breast cancer patients","volume":"273","author":"Iagaru","year":"2014","journal-title":"Radiology."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2967\/jnumed.112.117218","article-title":"89Zr-bevacizumab PET imaging in primary breast cancer","volume":"54","author":"Gaykema","year":"2013","journal-title":"J Nucl Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.seminoncol.2010.11.001","article-title":"Metabolic tumor imaging using magnetic resonance spectroscopy","volume":"38","author":"Glunde","year":"2011","journal-title":"Semin Oncol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3389\/fonc.2016.00266","article-title":"Targeting phospholipid metabolism in cancer","volume":"6","author":"Cheng","year":"2016","journal-title":"Front Oncol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/RLU.0000000000003987","article-title":"Histopathological features of parathyroid adenoma and 18F-choline uptake in PET\/MR of primary hyperparathyroidism","volume":"47","author":"Liberini","year":"2022","journal-title":"Clin Nucl Med."},{"key":"B164","first-page":"80","article-title":"Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells","volume":"59","author":"Aboagye","year":"1999","journal-title":"Cancer Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"684629","DOI":"10.3389\/fonc.2021.684629","article-title":"The diagnostic role of 18F-choline, 18F-fluciclovine and 18F-PSMA PET\/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1097\/rlu.0000000000001350","article-title":"Breast cancer incidentally detected by 18F-choline PET\/CT in a patient with recurrent prostate carcinoma","volume":"41","author":"Vadrucci","year":"2016","journal-title":"Clin Nucl Med."},{"key":"B167","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1158\/1078-0432.CCR-09-0666","article-title":"[11C]choline positron emission tomography in estrogen receptor-positive breast cancer","volume":"15","author":"Contractor","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B168","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1158\/1078-0432.CCR-10-0468","article-title":"Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab","volume":"16","author":"Kenny","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B169","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/RLU.0b013e3181c7c019","article-title":"Detection of synchronous primary breast and prostate cancer by F-18 fluorocholine PET\/CT","volume":"35","author":"Kwee","year":"2010","journal-title":"Clin Nucl Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1177\/0300060518773019","article-title":"PET\/CT analysis of 21 patients with breast cancer: physiological distribution of 18 F-choline and diagnostic pitfalls","volume":"46","author":"Ahmad Saad","year":"2018","journal-title":"J Int Med Res."},{"key":"B171","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls","volume":"38","author":"Hofman","year":"2018","journal-title":"Radiographics."},{"key":"B172","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0378-1119(02)00397-9","article-title":"Upregulation of prostate specific membrane antigen\/folate hydrolase transcription by an enhancer","volume":"285","author":"Noss","year":"2002","journal-title":"Gene."},{"key":"B173","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2967\/jnumed.117.203570","article-title":"Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms","volume":"59","author":"Roberto","year":"2018","journal-title":"J Nucl Med."},{"key":"B174","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/apm.12195","article-title":"Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers","volume":"122","author":"Wernicke","year":"2014","journal-title":"APMIS."},{"key":"B175","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/J.CLGC.2018.11.020","article-title":"Male breast cancer detected by 68 Ga-PSMA-11 PET\/CT in a patient with prostate cancer with pelvic lymph node metastasis","volume":"17","author":"Polverari","year":"2019","journal-title":"Clin Genitourin Cancer."},{"key":"B176","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/RLU.0000000000002086","article-title":"Re: false positive uptake in bilateral gynecomastia on 68Ga-PSMA PET\/CT scan","volume":"43","author":"Daglioz Gorur","year":"2018","journal-title":"Clin Nucl Med."},{"key":"B177","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/RLU.0000000000002063","article-title":"Synchronous detection of male breast cancer and prostatic cancer in a patient with suspected prostatic carcinoma on 68Ga-PSMA PET\/CT imaging","volume":"43","author":"Kumar","year":"2018","journal-title":"Clin Nucl Med."},{"key":"B178","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/RLU.0000000000002103","article-title":"68Ga-labeled PSMA uptake in nonprostatic malignancies: has the time come to remove \u201cpS\u201d from PSMA?","volume":"43","author":"Malik","year":"2018","journal-title":"Clin Nucl Med."},{"key":"B179","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.remn.2017.04.004","article-title":"Met\u00e1stasis cerebral \u00fanica, evidenciada mediante PET\/TC con 68Ga-PSMA en recurrencia de c\u00e1ncer de mama","volume":"37","author":"Medina-Ornelas","year":"2018","journal-title":"Rev Esp Med Nucl Imagen Mol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1097\/RLU.0000000000002265","article-title":"68Ga-prostate-specific membrane antigen PET\/CT and 18F-FDG PET\/CT of primary signet ring cell breast adenocarcinoma","volume":"43","author":"Parihar","year":"2018","journal-title":"Clin Nucl Med."},{"key":"B181","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/RLU.0000000000002071","article-title":"68Ga-prostate-specific membrane antigen PET\/CT in triple-negative breast cancer","volume":"43","author":"Passah","year":"2018","journal-title":"Clin Nucl Med."},{"key":"B182","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10549-018-4717-y","article-title":"Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy","volume":"169","author":"Tolkach","year":"2018","journal-title":"Breast Cancer Res Treat."},{"key":"B183","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1097\/RLU.0000000000001742","article-title":"False positive uptake in bilateral gynecomastia on 68Ga-PSMA PET\/CT scan","volume":"42","author":"Sasikumar","year":"2017","journal-title":"Clin Nucl Med."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1007\/s00259-015-3066-x","article-title":"68Ga-PSMA imaging of metastatic breast cancer","volume":"42","author":"Sathekge","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B185","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00259-016-3563-6","article-title":"68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients","volume":"44","author":"Sathekge","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B186","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.3390\/cancers13184543","article-title":"Nsclc biomarkers to predict response to immunotherapy with checkpoint inhibitors (Ici): from the cells to in vivo images","volume":"13","author":"Liberini","year":"2021","journal-title":"Cancers."},{"key":"B187","doi-asserted-by":"publisher","first-page":"752689","DOI":"10.3389\/fonc.2021.752689","article-title":"Editorial: immunotherapy as an evolving approach for the treatment of breast cancer","volume":"11","author":"Tolba","year":"2021","journal-title":"Front Oncol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"e002597","DOI":"10.1136\/jitc-2021-002597","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer","volume":"9","author":"Emens","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B189","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.3390\/molecules26082201","article-title":"The future of cancer diagnosis, treatment and surveillance: a systemic review on immunotherapy and immuno-pet radiotracers","volume":"26","author":"Liberini","year":"2021","journal-title":"Molecules."},{"key":"B190","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/ELIFE.57243","article-title":"Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy","volume":"9","author":"Barrett","year":"2020","journal-title":"Elife."},{"key":"B192","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/vaccines9060634","article-title":"Fibroblasts influence the efficacy, resistance, and future use of vaccines and immunotherapy in cancer treatment","volume":"9","author":"Sliker","year":"2021","journal-title":"Vaccines."},{"key":"B193","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1007\/s00259-021-05475-0","article-title":"State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis","volume":"48","author":"Sollini","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J Nucl Med."},{"key":"B195","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med."},{"key":"B196","unstructured":"Intensity of tracer-uptake in FAPI-PET\/CT in different kinds of cancer289\n            GieselF\n            FlechsigP\n            LabidiA\n            RathkeH\n            RathkeM\n            DebusJ\n          30954939J Nucl Med602019"},{"key":"B197","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2214\/AJR.20.24302","article-title":"Will FAPI PET\/CT replace FDG PET\/CT in the next decade? Point\u2014an important diagnostic, phenotypic, and biomarker role","volume":"216","author":"Calais","year":"2021","journal-title":"Am J Roentgenol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s12149-021-01672-x","article-title":"Superiority of 68Ga-FAPI PET\/CT scan in detecting additional lesions compared to 18FDG PET\/CT scan in breast cancer","volume":"35","author":"Elboga","year":"2021","journal-title":"Ann Nucl Med."},{"key":"B199","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s12149-021-01616-5","article-title":"68Ga-FAPI-04 PET\/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET\/CT","volume":"35","author":"K\u00f6mek","year":"2021","journal-title":"Ann Nucl Med."},{"key":"B200","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2967\/jnumed.119.233122","article-title":"Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu- And 225Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models","volume":"61","author":"Watabe","year":"2020","journal-title":"J Nucl Med."},{"key":"B201","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/RLU.0000000000003667","article-title":"Safety of fibroblast activation protein-targeted radionuclide therapy by a low-dose dosimetric approach using 177Lu-FAPI04","volume":"46","author":"Kuyumcu","year":"2021","journal-title":"Clin Nucl Med."},{"key":"B202","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-021-00130-3","article-title":"Fully-automated synthesis of 177Lu labelled FAPI derivatives on the module modular lab-Eazy","volume":"6","author":"Eryilmaz","year":"2021","journal-title":"EJNMMI Radiopharm Chem."},{"key":"B203","doi-asserted-by":"publisher","first-page":"E410","DOI":"10.1097\/RLU.0000000000003678","article-title":"Theranostic approach in breast cancer: a treasured tailor for future oncology","volume":"46","author":"Jokar","year":"2021","journal-title":"Clin Nucl Med."},{"key":"B204","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.3390\/cancers13225766","article-title":"Radiolabeled bombesin analogs","volume":"13","author":"Mansi","year":"2021","journal-title":"Cancers."},{"key":"B205","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bbcan.2006.01.003","article-title":"Gastrin-releasing peptide and cancer","volume":"1766","author":"Patel","year":"2006","journal-title":"Biochim Biophys Acta Rev Cancer."},{"key":"B206","doi-asserted-by":"publisher","first-page":"220","DOI":"10.7150\/thno\/v01p0220","article-title":"18 F-labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging","volume":"1","author":"Yang","year":"2012","journal-title":"Theranostics."},{"key":"B207","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2967\/JNUMED.119.234971","article-title":"Imaging the distribution of gastrin-releasing peptide receptors in cancer","volume":"61","author":"Baratto","year":"2020","journal-title":"J Nucl Med."},{"key":"B208","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00259-019-04503-4","article-title":"Physiological 68Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements","volume":"47","author":"Baratto","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B209","first-page":"1139","article-title":"Bombesin receptor subtypes in human cancers: detection with the universal radioligand 125I-[D-TYR6, \u03b2-ALA11, PHE13, NLE14] bombesin(6-14)","volume":"8","author":"Reubi","year":"2002","journal-title":"Clin Cancer Res."},{"key":"B210","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.peptides.2015.03.004","article-title":"GRPR-selective PET imaging of prostate cancer using [18F]-lanthionine-bombesin analogs","volume":"67","author":"Carlucci","year":"2015","journal-title":"Peptides."},{"key":"B211","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.bmc.2015.02.009","article-title":"18F-AmBF3-MJ9: a novel radiofluorinated bombesin derivative for prostate cancer imaging","volume":"23","author":"Pourghiasian","year":"2015","journal-title":"Bioorganic Med Chem."},{"key":"B212","doi-asserted-by":"publisher","first-page":"e210905","DOI":"10.1371\/journal.pone.0210905","article-title":"Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68 Ga-RM2 and 18 F-FDG in breast cancer samples","volume":"14","author":"Morgat","year":"2019","journal-title":"PLoS ONE."},{"key":"B213","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.7150\/thno.14958","article-title":"Gastrin-releasing peptide receptor imaging in breast cancer using the receptor antagonist 68Ga-RM2 And PET","volume":"6","author":"Stoykow","year":"2016","journal-title":"Theranostics."},{"key":"B214","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nucmedbio.2020.05.003","article-title":"Association between gastrin-releasing peptide receptor expression as assessed with [68Ga]Ga-RM2 PET\/CT and histopathological tumor regression after neoadjuvant chemotherapy in primary breast cancer","author":"Michalski","year":"2020","journal-title":"Nucl Med Biol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.3390\/cancers13236106","article-title":"Gastrin-Releasing peptide receptor antagonist [68Ga]RM2 PET\/CT for staging of pre-treated, metastasized breast cancer","volume":"13","author":"Michalski","year":"2021","journal-title":"Cancers."},{"key":"B216","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3390\/jcm9051452","article-title":"Neuroendocrine cancer of the breast: a rare entity","volume":"9","author":"Irelli","year":"2020","journal-title":"J Clin Med."},{"key":"B217","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41379-021-00736-7","article-title":"Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification","volume":"34","author":"Tsang","year":"2021","journal-title":"Mod Pathol."},{"key":"B218","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.radcr.2020.05.054","article-title":"Incidental primary breast cancer detected on surveillance 68Ga-DOTATATE PET\/CT in a patient with metastatic neuroendocrine carcinoma","volume":"15","author":"Ambinder","year":"2020","journal-title":"Radiol Case Rep."},{"key":"B219","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3413\/nukmed-0185","article-title":"Incidental detection of breast cancer by 68Ga-DOTATOC-PET\/CT in women suffering from neuroendocrine tumours","volume":"47","author":"Elgeti","year":"2008","journal-title":"NuklearMedizin."},{"key":"B220","unstructured":"Neuroendocrine carcinoma of the breast. Our experience and a proposal of a therapeutic algorithm for a rare tumor2036\n            ScaramuzziG\n            MurgoRM\n            CuttittaA\n            CiuffredaL\n          18507954G Chir.292008"},{"key":"B221","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000343612","article-title":"Peptide Receptor Radionuclide Therapy (PRRT) in a patient affected by metastatic breast cancer with neuroendocrine differentiation","volume":"7","author":"Savelli","year":"2012","journal-title":"Breast Care."},{"key":"B222","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2011\/967419","article-title":"Multidrug resistance in breast cancer: from in vitro models to clinical studies","volume":"2011","author":"Wind","year":"2011","journal-title":"Int J Breast Cancer."},{"key":"B223","doi-asserted-by":"publisher","first-page":"774","DOI":"10.2174\/138920011798356980","article-title":"PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo","volume":"12","author":"Mairinger","year":"2011","journal-title":"Curr Drug Metab."},{"key":"B224","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2967\/jnumed.111.091587","article-title":"Human dosimetry and preliminary tumor distribution of 18F- fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET\/CT","volume":"52","author":"Kurdziel","year":"2011","journal-title":"J Nucl Med."},{"key":"B225","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.2174\/0929867327666200612152655","article-title":"Radiolabeled peptides for molecular imaging of apoptosis","volume":"27","author":"Mosayebnia","year":"2020","journal-title":"Curr Med Chem."},{"key":"B226","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s11307-012-0551-5","article-title":"Longitudinal PET imaging of doxorubicin-induced cell death with 18F-annexin v","volume":"14","author":"Hu","year":"2012","journal-title":"Mol Imaging Biol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1021\/bc800164d","article-title":"Site-specific labeling of annexin V with F-18 for apoptosis imaging","volume":"19","author":"Li","year":"2008","journal-title":"Bioconjug Chem."},{"key":"B228","unstructured":"2-(5-[18F]Fluoro-pentyl)-2-methyl-malonic acid (ML-10)\n            ChopraA\n          Bethesda, MDNational Center for Biotechnology InformationMolecular Imaging and Contrast Agent Database (MICAD)"},{"key":"B229","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.3390\/ijms22083948","article-title":"Molecular imaging of apoptosis: the case of caspase-3 radiotracers","volume":"22","author":"Beroske","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B230","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1007\/s00259-018-4098-9","article-title":"Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3\/7 activation in breast and lung cancer","volume":"45","author":"Dubash","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B231","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1155\/2017\/5478068","article-title":"Normal uptake of 11C-acetate in pancreas, liver, spleen, and suprarenal gland in PET","volume":"2017","author":"Malkowski","year":"2017","journal-title":"Can J Gastroenterol Hepatol."},{"key":"B232","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2310\/7290.2011.00043","article-title":"[18F]fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases: an alternative tracer for [11c]acetate?","volume":"11","author":"Ho","year":"2012","journal-title":"Mol Imaging."},{"key":"B233","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1158\/1078-0432.CCR-17-3693","article-title":"[18F]fluorocholine and [18F]fluoroacetate PET as imaging biomarkers to assess phosphatidylcholine and mitochondrial metabolism in preclinical models of TSC and LAM","volume":"24","author":"Verwer","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B234","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.2967\/jnumed.116.175596","article-title":"18F-fluoroestradiol PET: current status and potential future clinical applications","volume":"57","author":"Liao","year":"2016","journal-title":"J Nucl Med."},{"key":"B235","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.2967\/JNUMED.118.220566","article-title":"Future of theranostics: an outlook on precision oncology in nuclear medicine","volume":"60","author":"Langbein","year":"2019","journal-title":"J Nucl Med."},{"key":"B236","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/pharmaceutics13050723","article-title":"Current state of breast cancer diagnosis, treatment, and theranostics","volume":"13","author":"Bhushan","year":"2021","journal-title":"Pharmaceutics."},{"key":"B237","doi-asserted-by":"publisher","first-page":"626","DOI":"10.7150\/ijms.49544","article-title":"Insights into the theranostic value of precision medicine on advanced radiotherapy to breast cancer","volume":"18","author":"Jiang","year":"2021","journal-title":"Int J Med Sci."},{"key":"B238","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.881551\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T05:27:32Z","timestamp":1649741252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.881551\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":238,"alternative-id":["10.3389\/fmed.2022.881551"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.881551","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"article-number":"881551"}}